| Autor: |
Cho, S., Nair, R., Jacobs, R., Devata, S., Gaballa, S., Yoon, D. H., Stevens, D. A., Kim, J. S., Shah, N. N., Brennan, D. M., Law, J., Lesley, R., Chen, R., Forcina, A., Buelow, B., Hou, J. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p127-129, 3p |
| Abstrakt: |
Escalating fixed TNB-486 doses (0.03-2.4 mg) without priming were evaluated prior to implementing single (day [D] 1) and double priming doses (D1 & 8) prior to target dose (D15). B Introduction: b Follicular lymphoma (FL) is incurable with a relapsing/remitting pattern and decreasing progression-free survival (PFS) interval per recurrence. HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text